Aurobin ointment 20.0g №1

Name: Aurobin ointment for nar. in tubes 20.0 g in a pack. No. 1 Description: Homogeneous ointment of white or almost white color, almost odorless Main active ingredient Glucocorticosteroid + antimicrobial agent Release form Ointment Dosage 20 g Pharmacological properties Pharmacodynamics Aurobin ointment contains active ingredients that are effective in inflammatory diseases in the anus. Prednisolone is a non-halogenated glucocorticosteroid with local anti-inflammatory activity. In addition, prednisolone reduces vascular permeability, increases the tone of the walls of blood vessels and reduces the symptoms of inflammation. Lidocaine quickly eliminates pain and burning. Panthenol promotes the regeneration of damaged epithelium and mucous membranes. Pharmacokinetics Studies of the pharmacokinetics of the ointment have not been conducted. Prednisolone Absorption When used topically, prednisolone can be absorbed and thus have a systemic effect (especially when the drug is applied to the skin under a sealed bandage or on damaged skin, and also in the case of a rectal enema ointment). Distribution Prednisolone is rapidly distributed in tissues, binds well to plasma proteins, crosses the placental barrier and can pass into breast milk. Elimination Prednisolone is excreted in the urine as conjugated metabolites. Lidocaine Absorption Lidocaine is well absorbed from the surface of mucous membranes and damaged skin. Distribution Lidocaine crosses the placental and blood-brain barriers and passes into breast milk. Biotransformation Lidacoin is mainly metabolized in the liver. Elimination Lidacoin binds well to plasma proteins, the half-life is 1-2 hours. Impaired renal function does not affect the rate of excretion of the parent compound, however, in this case, accumulation of the active metabolite may occur. Route of administration and doses Doses Adults and the elderly It is recommended to apply Aurobin ointment to the affected area of the body 2-4 times a day. As the severity of symptoms decreases, the ointment can be applied less frequently. The duration of therapy should be no more than 5-7 days. Children Aurobin is not intended for use in children under 1 year of age. The use of this drug in children older than 1 year is possible only in exceptional cases and in the smallest doses sufficient to achieve a therapeutic effect. The duration of treatment should not exceed 5 days. To minimize side effects, the drug should be applied to the affected areas no more than 2 times a day. Method of application For topical use only. Regardless of the age of the patient, prolonged use or application of the drug to large areas of skin or body folds should be avoided. It is not recommended to apply the ointment to the skin under a sealed bandage. Use during pregnancy and lactation Pregnancy Local use of glucocorticosteroids in pregnant women can cause damage to the fetus (eg, cleft palate and intrauterine defects). Information on safety when using the drug in pregnant women is not enough. Thus, Aurobin ointment should not be used in the first trimester of pregnancy; subsequently, the drug can be used only after a thorough assessment of the expected benefits and possible risks. Breast-feeding Glucocorticosteroids and lidocaine pass into breast milk. Glucocorticosteroids may affect adrenal function in neonates and may lead to developmental abnormalities. Small amounts of lidocaine are found in breast milk. Despite the fact that this practically does not pose a risk to the child, great care should be taken when using the drug in lactating women. Precautions If irritation or soreness of the skin occurs, treatment should be stopped immediately and appropriate supportive therapy instituted. Local and systemic toxic effects can be prevented by avoiding the application of the ointment to large or damaged areas of the skin, skin folds, under sealed dressings and for a long time. At the site of application of Aurobin ointment, especially in young patients, with prolonged use, skin atrophy may develop. In the case of fungal or bacterial infections, appropriate topical or systemic therapy is necessary. The use of the drug requires increased caution in patients with diabetes mellitus, tuberculosis and anemia, as well as in pediatric patients due to the possibility of suppressing the hypothalamic-pituitary-adrenal axis under the influence of the glucocorticosteroid that is part of the drug. Visual disturbances During the use of glucocorticosteroids of local and systemic action, visual disturbances may occur. If blurred vision or other visual disturbances occur, the patient should be referred to an ophthalmologist for possible causes, which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSC). These diseases can occur after the use of local and systemic glucocorticosteroids. Aurobin ointment contains methyl parahydroxybenzoate (E218), cetyl alcohol and propylene glycol (E1520) as excipients. Methyl parahydroxybenzoate (a substance also known as paraben) can cause allergic reactions (possibly delayed). Cetyl alcohol may cause local skin reactions (eg contact dermatitis). Propylene glycol may cause skin irritation. Interaction with other drugs No drug interaction studies have been conducted with Aurobin ointment. Aurobin ointment should not be used when lidocaine is co-administered for other indications. It should be used with caution in conjunction with other antiarrhythmic drugs. Contraindications - Hypersensitivity to the active ingredients or to any of the excipients listed in the "Composition" section. - Hypersensitivity to local anesthetics of the amide group (bupivacaine, etidocaine, mepivacaine and prilocaine). - Do not allow the drug to get into the eyes or on the skin around the eyes. - Primary bacterial, viral or fungal infections of the skin (eg herpes simplex). - Facial rosacea, acne vulgaris, perioral dermatitis, diaper rash, skin tuberculosis, skin manifestations of syphilis, dry small-lamellar peeling of the skin. - Simultaneous administration of lidocaine for other indications. - Age up to 1 year. - First trimester of pregnancy (see section "Use during pregnancy and during breastfeeding"). Ingredients: 1 g of ointment contains 2 mg of prednisolone capronate, 20 mg of lidocaine hydrochloride and 20 mg of dexpanthenol. Excipients: polysorbate 60, triclosan, methyl parahydroxybenzoate, cetyl alcohol, glycerin, propylene glycol, liquid paraffin, macrogol stearate, dimethicone, neutral oil, stearic acid, purified water. Overdose Depending on the amount of absorbed steroids and lidocaine, local or systemic manifestations may occur. There is no specific antidote, supportive therapy is indicated. Side effects When local application of glucocorticosteroids may occur predominantly local adverse reactions. Depending on the amount of steroids and lidocaine absorbed by the skin, their systemic effects may occur. With prolonged topical use of glucocorticosteroids or when they are applied to large surfaces of the body, suppression of adrenal function may develop. Especially often this phenomenon is observed in children and when Aurobin ointment is applied to the skin under a sealed bandage. Protein catabolism can lead to a negative nitrogen balance. Systemic absorption of lidocaine in a sufficiently large amount after topical application can cause stimulation and / or depression of the central nervous system. The frequency of occurrence of adverse events has not been established (cannot be determined based on the available data). Class of organ systems Undesirable effects Infections and invasions Exacerbation of latent infectious diseases Smoothing out the manifestations of infectious diseases Opportunistic infections Immune system disorders Hypersensitivity reactions Endocrine system disorders Inhibition of the function of the adrenal cortex Metabolic and nutritional disorders Hypokalemic alkalosis Fluid retention Hypokalemia Ion retention sodium in the body Mental disorders Insomnia Mental disorders Nervous system disorders Convulsions Dizziness Headache Increased intracranial pressure Eye disorders Cataract* Subcapsular cataract Glaucoma Optic nipple edema Corneal ulcer Chorioretinopathy Blurred vision (see also Precautions section) Disorders on the part of the heart Heart failure Violation of the conduction of the heart Violations of the vessels Arterial hypertension Peripheral vasodilatation Gastrointestinal disorders Gastrointestinal bleeding Gastrointestinal bleeding Gastrointestinal perforation Esophagitis Pancreatitis Gastric ulcer Skin and subcutaneous tissue disorders Dermatitis Folliculitis (application site) Acne-like rashes Contact dermatitis Dryness and thinning of the skin Erythema Urticaria Hirsutism Hyperhidrosis Intertrigo Itching Skin atrophy Hypopigmentation Skin irritation Striae formation Telangiectasia Burning sensation of the skin Musculoskeletal and connective tissue disorders Steroid myopathy Osteonecrosis Osteoporosis General disorders and administration site disorders Delayed wound healing Laboratory and instrumental findings Increased intraocular pressure Negative nitrogen balance Delayed response in skin provocation tests Children *Children are more likely to develop cataracts. Growth retardation may occur. Storage conditionsStore at temperatures between +8 °C and +15 °C. Keep out of reach of children. Buy Aurobin ointment 20.0g No. 1 Price for Aurobin ointment 20.0 g No. 1 Instructions for use for Aurobin ointment 20.0 g No.